Lynch Regenerative Medicine Hires Hee as Chief Scientific Officer

Lynch Regenerative Medicine, LLC., (LRM) and its wholly owned subsidiaries LRM Aesthetics, Inc. (LRMA), and LRM WoundCare, Inc. (LRMW), announced today that Charlie Hee, Ph.D., will join its team as Chief Scientific Officer (CSO) across all companies, effective immediately.

Dr. Hee is an experienced translational scientist and strategic leader, with more than 20 years of industry and research experience. Trained in tissue engineering, with a doctorate from the University of Pennsylvania, Dr. Hee has a keen interest in novel product applications incorporating growth factors, stem cells and biologic scaffolds to drive regenerative healing. With experience in developing products for use in aesthetic medicine and reconstructive surgery, Dr. Hee was identified as an ideal fit for LRM’s focus areas in aesthetics and wound care.

“As CSO, Dr. Hee will have responsibility for leading all our teams in Phase I through IV clinical trials, non-clinical research, new product development, quality control, and manufacturing for LRM, LRMA and LRMW. His previous experience with recombinant pure PDGF, and the aesthetic and regenerative medicine fields, make him ideal to work with our current team members to drive further success in these areas,” stated Dr. Samuel Lynch, founder and CEO of LRM.

Most recently, Dr. Hee served as vice president of Device R&D at Allergan Aesthetics, an Abbvie company, with responsibility for device product development, biological research, and biomaterials and drug delivery in support of Allergan Aesthetic’s Fillers, Plastic and Regenerative Medicine, and Body Contouring franchises. Prior to that, Dr. Hee served as an associate director of research at BioMimetic Therapeutics, leading the scientific research evaluating recombinant pure platelet-derived growth factor-BB (PDGF-BB) for sports medicine and orthopedic applications.

About Lynch Regenerative Medicine, LLC

Lynch Regenerative Medicine, LLC., is pioneering innovative treatments that aim to revolutionize the $100 billion aesthetics and wound-care markets. Our mission is to leverage our regenerative medicine heritage, and our decades-long commitment to safe and effective regenerative products of the highest quality, to deliver exceptional results for our customers and their patients and thereby redefine the future of aesthetic regenerative medicine. The company was founded in 2023 by Dr. Lynch and is based in Franklin, Tennessee.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250507912524/en/